Meeder Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Meeder Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,701	Closed	-$97K	–	2507
2021 Q3	$97K	Buy	12,701 +335	+3%	+$2.84K	0.01%	904
2021 Q2	$120K	Buy	12,366 +5,776	+88%	+$46K	0.01%	855
2021 Q1	$55K	Buy	+6,590	New	+$69.6K	﹤0.01%	1076
2020 Q4	–	Sell	-8,031	Closed	-$90K	–	2340
2020 Q3	$90K	Buy	8,031 +646	+9%	+$5.91K	0.01%	814
2020 Q2	$46K	Buy	7,385 +6,762	+1,085%	+$25.9K	﹤0.01%	944
2020 Q1	$1K	Buy	+623	New	+$1.79K	﹤0.01%	2262
2019 Q2	–	Sell	-780	Closed	-$4K	–	2187
2019 Q1	$4K	Buy	+780	New	+$2.05K	﹤0.01%	1463
2018 Q4	–	Sell	-4,063	Closed	-$17K	–	1848
2018 Q3	$17K	Buy	+4,063	New	+$22.5K	﹤0.01%	1068
2018 Q2	–	Sell	-223	Closed	-$1K	–	1718
2018 Q1	$1K	Sell	223 -1,084	-83%	-$7.71K	﹤0.01%	1502
2017 Q4	$5K	Sell	1,307 -610	-32%	-$1.59K	﹤0.01%	1334
2017 Q3	$3K	Buy	1,917 +1,049	+121%	+$1.93K	﹤0.01%	1406
2017 Q2	$2K	Hold	868	–	–	﹤0.01%	1450
2017 Q1	$3K	Buy	868 +62	+8%	+$311	﹤0.01%	1294
2016 Q4	$4K	Buy	+806	New	+$4.84K	﹤0.01%	888

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Meeder Asset Management's SRNE Position: Q4 2021 in Review

Meeder Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2021, closing a stake of 12,701 shares — an estimated $97K sold.

Meeder Asset Management first reported a position in SRNE in Q4 2016 and held it in 14 quarters. The position peaked at $120K in Q2 2021. 234 funds tracked by Wall St. Rank hold SRNE as of Q4 2021.

Meeder Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 12,701 Sorrento Therapeutics, Inc. shares in Q4 2021, an estimated $97K.
Meeder Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2016 and held it in 14 quarters.
Meeder Asset Management's Sorrento Therapeutics, Inc. position peaked at $120K in Q2 2021.
234 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.